| Bioactivity | LY-503430 is an orally active AMPA receptor positive allosteric modulator (PAM). LY-503430 can be used for the study of Parkinson's disease[1]. |
| Invitro | 亚微摩尔浓度的 LY-503430（0.03-10 μM）选择性地增强谷氨酸诱导的钙流入转染了人 GLUA1、GLUA2、GLUA3 或 GLUA4 AMPA 受体的人胚胎肾 293 细胞。LY-503430 还能增强原生皮质、海马和黑质神经元中 AMPA 介导的反应[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LY-503430 相关抗体: |
| In Vivo | LY503430（0.5 mg/kg；皮下注射；每天一次；连续 11 天）在帕金森病啮齿动物模型中具有功能性、神经保护性和神经营养作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 625820-83-9 |
| Formula | C20H25FN2O3S |
| Molar Mass | 392.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tracey K Murray, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. |